



**Roger Nitsch**

Independent Member of the Board of Directors Lonza Group Ltd (from May 2022 until May 2026)

---

**Career**

---

2025 – present	Member of the Board of Directors, OphthaNova Therapeutics AG
2017 – present	Member of the Advisory Board, PUREOS Bioventures
2015 – present	Member of the Board of Directors, NOVAGO Therapeutics AG
2006 – present	CEO and President of the Board of Directors, Neurimmune Group
2002 – present	Member of the Board of Directors, INTEGRA Biosciences Holding AG
2022 – 2026	Independent Member of the Board of Directors, Lonza Group Ltd
2016 – 2020	Director and co-founder of the Institute for Regenerative Medicine University of Zurich
2016 – 2018	Overseas Visiting Professor of Health Science Aino University, Osaka, Japan
2009 – 2012	Member of the Advisory Board Max-Planck-Institute for Psychiatry, Munich
2006 – 2012	Member and Chair of the Scientific Advisory Board Institute for Advanced Studies
2002 – 2014	Chair, Board of Trustees, Center for Clinical Research University Hospital Zurich
2002 – 2008	Vice Dean Research, Medical Faculty at the University of Zurich
1999 – 2006	Coordinator of the European Union DIADEM and APOPIS Research Consortia

---

1998 – 2005	Director at the Psychiatric University Hospital Zurich
1998 – 2024	Professor at the University of Zurich
1995 – 1998	Member of the Board of Directors and co-founder EVOTEC Neurosciences
1990 – 1995	Post-Doc, M.I.T. and Harvard Medical School
1987 – 1990	Post-Doc, University of Heidelberg
1983 – 1987	Research Fellow, Max-Planck Institute for Medical Research, Heidelberg

---

### **Education**

---

MD degree from the University of Heidelberg (DE)  
Post-doctoral qualification at the Massachusetts Institute of Technology and Harvard Medical School